Marco Gobbi

Università degli Studi di Genova, Italy

Marco Gobbi was born in 1948. He has got his M.D. degree in 1972 at the University of Bologna, Bologna, Italy. In 1975, Gobbi became a Specialist in hematology at the University of Bologna. Furthermore, in 1978, he became a Specialist in oncology at the University of Modena. From 1981 to 1990, Gobbi was a Senior Researcher at the Seragnoli Institute of Haematology at the University of Bologna. In addition, since 1990 and until today, he is a Full Professor of hematology, Head of the Clinical Hematology, and Director of Postgraduate School of Hematology at the University of Genoa. In 1974, Gobbi studied immunology and immunotherapy of acute myeloid leukemias in The Royal Marsden Hospital, Sutton, Surrey, UK with Dr. Ray Powles. Moreover, in 1981, he studied the normal counterpart of B-cell malignancies and developed monoclonal antibodies to B cells in the Royal Free Hospital, London, UK with Professor George Janossy. In 1982, in collaboration with Caligaris-Cappio and George Janossy, Gobbi demonstrated the existence of B-cell CD5+ in normal tissue, as putative normal counterpart of B CLL, while in 1983, using a range of new monoclonal antibodies to B cell he developed at the Royal Free Hospital, he proposed a general scheme of cellular derivation of B-cell malignancy. In 1984, with Stefano Pileri, he published the first immunoistochemical evaluation of cell proliferation in lymphomas using monoclonal antibodies to transferrin receptors. Between 1985 and 1989, his main interest has been the development of a method to purge bone marrows of multiple myeloma patients. More recently, he has extensively studied the effects of fludarabine in low-grade lymphoproliferative disorders. Recently, Gobbi developed new therapeutic approaches using fludarabine containig protocols for the treatment of acute myeloid leukemias and myelodisplastic syndromes. During the last years, he addressed the problem of the minimal residual disease in B cell malignancies as well as prognosis of AML using original molecular biological techniques. Gobbi is the author of more than 270 scientific papers scored on Pub Med. His main clinical interest is devoted to acute leukemias, multiple myeloma, and lymphomas.

Biography Updated on 2 December 2010

Scholarly Contributions [Data Provided by scopus]